Impact of Clot Shape on Successful M1 Endovascular Reperfusion
- PMID: 33597919
- PMCID: PMC7882685
- DOI: 10.3389/fneur.2021.642877
Impact of Clot Shape on Successful M1 Endovascular Reperfusion
Abstract
Objectives: The susceptibility-vessel-sign (SVS) allows thrombus visualization, length estimation and composition, and it may impact reperfusion during mechanical thrombectomy (MT). SVS can also describe thrombus shape in the occluded artery: in the straight M1-segment (S-shaped), or in an angulated/traversing a bifurcation segment (A-shaped). We determined whether SVS clot shape influenced reperfusion and outcomes after MT for proximal middle-cerebral-artery (M1) occlusions. Methods: Between May 2015 and March 2018, consecutive patients who underwent MT at one comprehensive stroke center and who had a baseline MRI with a T2* sequence were included. Clinical, procedural and radiographic data, including clot shape on SVS [angulated/bifurcation (A-SVS) vs. straight (S-SVS)] and length were assessed. Primary outcome was successful reperfusion (TICI 2b-3). Secondary outcome were MT complication rates, MT reperfusion time, and clinical outcome at 90-days. Predictors of outcome were assessed with univariate and multivariate analyses. Results: A total of 62 patients were included. 56% (35/62) had an A-SVS. Clots were significantly longer in the A-SVS group (19 mm vs. 8 mm p = 0.0002). Groups were otherwise well-matched with regard to baseline characteristics. There was a significantly lower rate of successful reperfusion in the A-SVS cohort (83%) compared to the S-SVS cohort (96%) in multivariable analysis [OR 0.04 (95% CI, 0.002-0.58), p = 0.02]. There was no significant difference in long term clinical outcome between groups. Conclusion: Clot shape as determined on T2* imaging, in patients presenting with M1 occlusion appears to be a predictor of successful reperfusion after MT. Angulated and bifurcating clots are associated with poorer rates of successful reperfusion.
Keywords: clot; endovascular recanalization; magnetic resonance imaging; stroke; thrombectomy.
Copyright © 2021 Guenego, Fahed, Sussman, Leipzig, Albers, Martin, Marcellus, Kuraitis, Marks, Lansberg, Wintermark and Heit.
Conflict of interest statement
GA reports equity and consulting for iSchemaView and consulting from Medtronic. MM reports Ownership Interest in ThrombX Medical. JH reports Consultant or Advisory Board for Medtronic, Inc., MicroVention, Inc., and iSchemaView. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
